Original Article

You have full text access to this OnlineOpen article

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma

Implications for clinical trials in this patient population

  1. Jeremy G. Perkins M.D.1,
  2. Joseph M. Flynn D.O.1,
  3. Robin S. Howard M.A.2,
  4. John C. Byrd M.D.3,†,*

Article first published online: 4 APR 2002

DOI: 10.1002/cncr.0680

Issue

Cancer

Cancer

Volume 94, Issue 7, pages 2033–2039, 1 April 2002

Additional Information

How to Cite

Perkins, J. G., Flynn, J. M., Howard, R. S. and Byrd, J. C. (2002), Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma. Cancer, 94: 2033–2039. doi: 10.1002/cncr.0680

Author Information

  1. 1

    Department of Medicine, Walter Reed Army Medical Center, Washington, D.C

  2. 2

    Department of Clinical Investigation, Walter Reed Army Medical Center, Washington, D.C

  3. 3

    Division of Hematology-Oncology, The Ohio State University, Columbus, Ohio

  1. †

    Fax: (614) 293-7526

*Division of Hematology-Oncology, The Ohio State University, B301 Starling Loving Hall, 320 West 10th Avenue, Columbus, Ohio 43210-1240

Publication History

  1. Issue published online: 4 APR 2002
  2. Article first published online: 4 APR 2002
  3. Manuscript Accepted: 13 DEC 2001
  4. Manuscript Revised: 5 JUL 2001
  5. Manuscript Received: 28 DEC 2000

Funded by

  • Chronic Lymphocytic Leukemia Research Consortium. Grant Number: P01 CA81534-02
  • Sidney Kimmel Cancer Research Foundation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (80K)

REFERENCES

  • 1
    Deisseroth AB, Kantarjian H, Andreeff M, et al. Chronic leukemias. In: DeVitaVT, JellmanS, RosenbergSA, editors. Cancer, principles and practice of oncology. 5th ed. Philadelphia: JB Lippincott Company, 1997: 2321–2326.
  • 2
    Rozman C, Montserrat E. Current concepts: chronic lymphocytic leukemia. N Engl J Med. 1995; 336: 1052–1057.
  • 3
    Montserrat E, Gomis F, Vallespi T, et al. Presenting features and prognosis of chronic lymphocytic leukemia in younger adults. Blood. 1991; 78: 1545–1551.
  • 4
    Leporrier M, Chevret S, Cazin B, Binet JL. Randomized comparison of fludarabine, CAP, and CHOP in 695 previously untreated stage B and C chronic lymphocytic leukemia(CLL). Early stopping of the CAP accrual [abstract]. Blood. 1997; 90: 529.
  • 5
    Rai KR, Peterson B, Elias L, et al. A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C, and ECOG Inter-group study [abstract]. Blood. 1996; 88: 141.
  • 6
    Johnson S, Smith AG, Loffler H, et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet. 1996; 347: 1432–1438.
  • 7
    Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998; 338: 1506–1514.
  • 8
    Sorensen JM, Vena DA, Fallavollita A, Chun HG, Chesson BD. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: five-year follow-up report. J Clin Oncol. 1997; 15: 458–465.
  • 9
    De Rossi G, Mauro FR, Caruso R, Monarca B, Mandelli F. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages. Haematologica. 1993; 78: 167–171.
  • 10
    Stelitano C, Morabito F, Kropp MG, et al. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases. Haematologica. 1999; 84: 317–323.
  • 11
    Zinzani PL, Lauria F, Rondelli D, et al. Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur J Haematol. 1993; 51: 93–97.
    Direct Link:
  • 12
    Spriano M, Clavio M, Carrara P, et al. Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. Haematologica. 1994; 79: 218–224.
  • 13
    Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998; 92: 1165–1171.
  • 14
    Montserrat E, Lopez-Lorenzo JL, Manso F, et al. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: the Spanish Group experience. Leuk Lymphoma. 1996; 21: 467–472.
  • 15
    Byrd JC, Rai KR, Sausville EA, Grever MR. Old and new therapies in chronic lymphocytic leukemia: now is the time for a reassessment of therapeutic goals. Semin Oncol. 1998; 25: 65–74.
  • 16
    Clendeninn NJ, Nethersell AB, Scott JE, Offenhauser KO, Collier MA. Early safety and efficacy results using Campath-1H (CP-1H), a humanized antilymphocyte monoclonal antibody (MAB), in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) [abstract]. Proc Annu Meet Am Soc Clin Oncol. 1993; 12: A1286.
  • 17
    Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol. 1997; 96: 617–619.
    Direct Link:
  • 18
    Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJ, Catovsky D. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol. 1996; 93: 151–153.
    Direct Link:
  • 19
    Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol. 1997; 15: 1567–1574.
  • 20
    Cheson BD, Bennett JM, Grever M. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990–4997.
  • 21
    Hainsworth JD, Burris HA 3rd, Morrissey LH. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood. 2000; 95: 3052–3056.
  • 22
    Keating MJ, Byrd JC, Rai K, et al. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine, Campath-1H collaborative study group [abstract]. Blood. 1999; 94 (Suppl 1): 3118.
  • 23
    Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998; 129: 559–566.
  • 24
    Morra E, Nosari A, Montillo M. Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther. 1999; 41: 145–151.
  • 25
    Chou MY, Brown AE, Blevins A, Armstrong D. Severe pneumococcal infection in patients with neoplastic disease. Cancer. 1983; 51: 1546–1550.
    Direct Link:
  • 26
    Nedialkova M, Georgieva V. Infectious complications of acute and chronic leukemia. Vutr Boles. 1979; 18: 103–107.
  • 27
    Travade P, Dusart JD, Cavaroc M, Beytout J, Rey M. Severe infections associated with chronic lymphoid leukemia. 159 infectious episodes in 60 patients. Presse Med. 1986; 15: 1715–1718.
  • 28
    Morison WL. Viral warts, herpes simplex, and herpes zoster in patients with secondary immune deficiencies and neoplasms. Br J Dermatol. 1975; 92: 625–630.
    Direct Link:
  • 29
    Byrd JC, McGrail LH, Hospenthal DR, Howard RS, Dow NA, Diehl LF. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol. 1999; 105: 445–447.
    Direct Link:
  • 30
    Sanders C, Perez EA, Lawrence HJ. Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine. Am J Hematol. 1992; 39: 314–315.
    Direct Link:
  • 31
    Fenchel K, Bergmann L, Wijermans P, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma. 1995; 18: 485–492.
View Full Article (HTML) Get PDF (80K)